Gainers

• China SXT Pharmaceuticals (NASDAQ:SXTC) shares rose 6.5% to $1.78 during Wednesday's after-market session. The market value of their outstanding shares is at $7.9 million.
• Cardiol Therapeutics (NASDAQ:CRDL) shares rose 6.24% to $1.19. The company's market cap stands at $132.5 million.
• Instil Bio (NASDAQ:TIL) shares moved upwards by 6.19% to $8.74. The company's market cap stands at $55.0 million.
• NervGen Pharma (NASDAQ:NGEN) shares rose 5.93% to $2.02. The company's market cap stands at $212.4 million.
• BioRestorative Therapies (NASDAQ:BRTX) shares moved upwards by 5.71% to $0.36. The market value of their outstanding shares is at $9.0 million.
• Orchestra BioMed Hldgs (NASDAQ:OBIO) shares increased by 5.18% to $4.06. The company's market cap stands at $234.1 million.

Losers

• ADC Therapeutics (NYSE:ADCT) stock decreased by 39.6% to $1.86 during Wednesday's after-market session. The market value of their outstanding shares is at $403.1 million.
• Basel Medical Group (NASDAQ:BMGL) shares declined by 19.24% to $0.53. The company's market cap stands at $10.3 million.
• Virax Biolabs Group (NASDAQ:VRAX) shares decreased by 12.5% to $0.21. The company's market cap stands at $1.6 million.
• FibroBiologics (NASDAQ:FBLG) shares declined by 6.55% to $1.0. The market value of their outstanding shares is at $5.4 million.
• Regentis Biomaterials (AMEX:RGNT) shares decreased by 6.22% to $1.66. The company's market cap stands at $8.5 million.
• Jade Biosciences (NASDAQ:JBIO) shares declined by 6.2% to $16.5. The company's market cap stands at $876.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.